Physician profile
Joseph E Charles
NPI 1245309624
$3,395.11
in general payments reported to CMS, 2019-2025
12 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $244 · 2021: $17.18 · 2022: $342 · 2023: $389 · 2024: $884 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.29 | 2019-2025 | Vraylar |
| Alkermes, INC. | $617.42 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $549.43 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $276.45 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $268.01 | 2020-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $173.95 | 2019-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $131.46 | 2019-2020 | |
| Allergan, INC. | $130.09 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.71 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $124.92 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $88.43 | 2019-2020 | |
| Lundbeck LLC | $46.95 | 2019-2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.